Biotronik Recordkeeping, Sponsor Oversight Lapses Lead To Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
Biotronik maintains it provided FDA with requested copies of clinical data during a recent inspection, rendering a 1June 4 warning letter to the firm unnecessary